Deutsche Bank Raises Roche Rating Following Cancer Drug Clinical Feedback

By EC Assets · Published 23 October 2026

Deutsche Bank upgraded Roche following bullish physician feedback regarding a cancer drug. The rating action marks a shift in stance for the European pharmaceutical company. Swiss drugs and diagnostics maker Roche trades on the SIX Swiss Exchange under the ticker RO. The company also trades in the United States over the counter under the ticker symbols RHHBY and RHHBF. The move by Deutsche Bank follows diverging sentiment among major financial brokerages covering the Swiss healthcare group. BofA Securities upgraded Roche to a buy rating, establishing a price target of CHF 340. The contrasting actions leave the drugs and diagnostics company facing mixed evaluations across major institutions. Prior to the upgrade, Deutsche Bank held a sell recommendation on Roche. The bank cut Roche to sell on a Friday following presentations of clinical data for the company's key pipeline candidates. That downgrade reflected analyst reactions to the latest trial readouts showcased by the European pharmaceutical major. Deutsche Bank's previous action on Roche occurred alongside a downgrade of fellow European pharmaceutical major AstraZeneca. Both drugmakers showcased the latest trial data for their key pipeline candidates during the same week. AstraZeneca trades on the Nasdaq under the ticker symbol AZN. Pipeline readouts and clinical trials have driven rating revisions across European pharmaceutical majors. While earlier trial data showcases led Deutsche Bank to reduce its ratings on both Roche and AstraZeneca, clinical feedback from physicians concerning oncology treatments provided the catalyst for the bank's reversal on Roche. Clinical trial data presentations and physician assessments for key pipeline candidates serve as ongoing reference points for broker evaluations across the European pharmaceutical sector. This article is intended for informational purposes only. It does not constitute investment advice.